Abstract
A new HPV-16/18 bivalent vaccine expressed by the Escherichia coli has been proven to be efficacious in adult women. A randomized, immunogenicity noninferiority study of this candidate vaccine was conducted in December 2015 in China. Girls aged 9–14 years were randomized to receive 2 doses at months 0 and 6 (n=301) or 3 doses at months 0, 1 and 6 (n=304). Girls aged 15–17 years (n=149) and women aged 18–26 years (n=225) received 3 doses. The objectives included noninferiority analysis of the IgG geometric mean concentration (GMC) ratio (95% CI, lower bound>0.5) to HPV-16 and HPV-18 at month 7 in girls compared with women. In the per-protocol set, the GMC ratio of IgG was noninferior for girls aged 9–17 years receiving 3 doses compared with women (1.76 (95% CI, 1.56, 1.99) for HPV-16 and 1.93 (95% CI, 1.69, 2.21) for HPV-18) and noninferior for girls aged 9–14 years receiving 2 doses compared with women (1.45 (95% CI, 1.25, 1.62) for HPV-16 and 1.17 (95% CI, 1.02, 1.33) for HPV-18). Noninferiority was also demonstrated for neutralizing antibodies. The immunogenicity of the HPV vaccine in girls receiving 3 or 2 doses was noninferior compared with that in young adult women.
Article PDF
Similar content being viewed by others
References
Block, S.L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K.E.D., Marchant, C. D., Castellsagué, X., Rusche, S.A., Lukac, S., Bryan, J.T., et al. (2006). Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in male and female adolescents and young adult women. Pediatrics 118, 2135–2145.
Bruni, L., Albero, G., Serrano, B., Mena, M., Gómez, D., Muñoz, J., Bosch, F. X., de Sanjosé, S. (2019). ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. http://www.hpvcentre.net.
Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X.Q., and He, J. (2016). Cancer statistics in China, 2015. CA-A Cancer J Clin 66, 115–132.
de Martel, C., Plummer, M., Vignat, J., and Franceschi, S. (2017). Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141, 664–670.
Dobson, S.R.M., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., Sauvageau, C., Scheifele, D.W., Kollmann, T.R., Halperin, S.A., et al. (2013). Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women: a randomized clinical trial. JAMA 309, 1793.
European Medicines Agency. Cervarix. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000721/WC500024632.pdf.
European Medicines Agency. Gardasil 9. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/003852/WC500189111.pdf.
European Medicines Agency. Gardasil. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000703/WC500021142.pdf.
Future II Study Group. (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med, 356, 1915–1927.
Gu, Y., Wei, M., Wang, D., Li, Z., Xie, M., Pan, H., Wu, T., Zhang, J., Li, S., and Xia, N. (2017). Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine 35, 4637–4645.
Harper, D.M., Franco, E.L., Wheeler, C., Ferris, D.G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N.S., et al. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364, 1757–1765.
Herrero, R., González, P., and Markowitz, L.E. (2015). Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 16, e206–e216.
Hu, Y.M., Huang, S.J., Chu, K., Wu, T., Wang, Z.Z., Yang, C.L., Cai, J.P., Jiang, H.M., Wang, Y.J., Guo, M., et al. (2014). Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: An open-label phase I clinical trial.. Human Vaccines Immun 10, 469–475.
Huang, X., Wang, X., Zhang, J., Xia, N., and Zhao, Q. (2017). Escherichia coli-derived virus-like particles in vaccine development. NPJ Vaccines 2, 3.
Iversen, O.E., Miranda, M.J., Ulied, A., Soerdal, T., Lazarus, E., Chokephaibulkit, K., Block, S.L., Skrivanek, A., Nur Azurah, A.G., Fong, S.M., et al. (2016). Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs. a 3-dose regimen in women. JAMA 316, 2411–2421.
Jingyee Kou, T. M., and A. Dale Horne. (2009). Statistical review and evaluation. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM206200.pdf.
Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., Moreira Jr., E.D., Ngan, Y., Petersen, L.K., Lazcano-Ponce, E., et al. (2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372, 711–723.
Joura, E.A., Kjaer, S.K., Wheeler, C.M., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., Perez, G., Brown, D.R., Koutsky, L.A., Tay, E.H., et al. (2008). HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26, 6844–6851.
Kjaer, S.K., Nygård, M., Dillner, J., Brooke Marshall, J., Radley, D., Li, M., Munk, C., Hansen, B.T., Sigurdardottir, L.G., Hortlund, M., et al. (2018). A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin Infect Dis 66, 339–345.
Liu, W., Wei, F., Tang, J., Yang, S., Gao, Y., Wang, T., Jiang, Y., Li, M., Hong, Y., Chu, K., et al. (2016). Detection of neutralizing antibodies and DNA of human papillomavirus 16, 18 in women aged 18-45 years in Funing, Jiangsu Province. Chin J Epidemiol, 37, 406–409.
Mariani, L., Cristoforoni, P., Perino, A., Stigliano, C. M. and Preti, M. (2016). Nonavalent HPV vaccine (HPV-9): Analysis of pre-registration data. Minerva Ginecol, 68, 620–621.
Olsson, S.E., Villa, L.L., Costa, R.L.R., Petta, C.A., Andrade, R.P., Malm, C., Iversen, O.E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2007). Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25, 4931–4939.
Pedersen, C., Petaja, T., Strauss, G., Rumke, H.C., Poder, A., Richardus, J. H., Spiessens, B., Descamps, D., Hardt, K., Lehtinen, M., et al. (2007). Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolescent Health 40, 564–571.
Qiao, Y.L., Wu, T., Li, R.C., Hu, Y.M., Wei, L.H., Li, C.G., Chen, W., Huang, S.J., Zhao, F.H., Li, M.Q., et al. (2019). Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial. J Natl Cancer Inst. (Epub ahead of print), https://doi.org/10.1093/jnci/djz074.
Romanowski, B., Schwarz, T.F., Ferguson, L.M., Peters, K., Dionne, M., Schulze, K., Ramjattan, B., Hillemanns, P., Catteau, G., Dobbelaere, K., et al. (2011). Immunogenicity and safety of the HPV-16/18 AS04- adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study.. Human Vaccines 7, 1374–1386.
Stanley, M., Lowy, D.R., and Frazer, I. (2006). Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 24, S106–S113.
Van Damme, P., Olsson, S.E., Block, S., Castellsague, X., Gray, G.E., Herrera, T., Huang, L.M., Kim, D.S., Pitisuttithum, P., Chen, J., et al. (2015). Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics 136, e28–e39.
World Health Organization. (2014). Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec, 89, 465–491.
World Health Organization. (2017). Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec, 92, 241–268.
World Health Organization. (2018). WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. http://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/.
Wu, T., Hu, Y.M., Li, J., Chu, K., Huang, S.J., Zhao, H., Wang, Z.Z., Yang, C.L., Jiang, H.M., Wang, Y.J., et al. (2015). Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Vaccine 33, 3940–3946.
Zhao, F.H., Tiggelaar, S.M., Hu, S.Y., Xu, L.N., Hong, Y., Niyazi, M., Gao, X.H., Ju, L.R., Zhang, L.Q., Feng, X.X., et al. (2012). A multi-center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiol 36, 384–390.
Zhao, H., Lin, Z.J., Huang, S.J., Li, J., Liu, X.H., Guo, M., Zhang, J., Xia, N.S., Pan, H.R., Wu, T., et al. (2014). Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Human Vaccines Immun 10, 740–746.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (81673240, and U1705283), the Chinese National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2018ZX09308010, 2012ZX09101316), the Fujian Provincial Major Scientific and Technological Project (2015YZ0002) and Xiamen Innovax.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Compliance and ethics
M.G., B.-Z.L., Z.-J.L., and H.-R.P. report being either current or former employees of Xiamen Innovax. No other potential conflict of interest relevant to this article by the other authors was reported. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Electronic supplementary material
11427_2019_9547_MOESM5_ESM.docx
Supplementary Table 4. Noninferiority Analysis of Geometric Mean Concentrations (GMCs) in girls who received 2 doses vs 3 doses
Rights and permissions
About this article
Cite this article
Hu, YM., Guo, M., Li, CG. et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci. China Life Sci. 63, 582–591 (2020). https://doi.org/10.1007/s11427-019-9547-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-019-9547-7